Acusphere Schedules Conference Call and Webcast to Present RAMP-2 Clinical Trial Results for Imagify(TM) (Perflubutane Polymer Microspheres) Injectable Suspension.Conference Call Scheduled for Tuesday, May 1, 2007, 8:30 AM ET WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ACUS acus (a´kus) a needle or needle-like process. acus a needle or needle-like process. ) today announced that it will host a conference call and webcast to discuss the top-level results from the second Imagify Phase 3 pivotal clinical trial, RAMP-2 on May 1, 2007, at 8:30 AM ET. The Company indicated that it intends on issuing, prior to the conference call, a press release summarizing the results of the trial. The conference call will include an opportunity for analyst and investor questions and answers. RAMP-2 trial results are scheduled to be presented by Sherri C. Oberg, President and Chief Executive Officer of Acusphere, Dr. Richard Walovitch, Senior Vice President of Clinical Research and Dr. Michael Picard, Director of Clinical Echocardiography Echocardiography Definition Echocardiography is a diagnostic test that uses ultrasound waves to create an image of the heart muscle. Ultrasound waves that rebound or echo off the heart can show the size, shape, and movement of the heart's valves and at Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world . This conference call and related slides will be accessible to hear and review via the Company's website at www.acusphere.com.
Dial in details:
Date: May 1, 2007
Time: 8:30 AM ET
Dial in: Domestic - 866-713-8564
International - 617-597-5312
Passcode: 10025502
About Imagify[TM] Imagify[TM] is an investigational new drug developed to assess perfusion perfusion /per·fu·sion/ (-zhun) 1. the act of pouring over or through, especially the passage of a fluid through the vessels of a specific organ. 2. a liquid poured over or through an organ or tissue. using ultrasound for the detection of coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. . Myocardial myocardial /myo·car·di·al/ (-kahr´de-al) pertaining to the muscular tissue of the heart. myocardial pertaining to the muscular tissue of the heart (the myocardium). perfusion is blood flow in the heart muscle and is a sensitive marker of coronary artery disease. Currently, perfusion information is not available using cardiac ultrasound but must be obtained using a nuclear stress test, which is the most frequently used imaging procedure for detecting coronary artery disease. Imagify is designed to provide real-time perfusion information with quicker results, lower cost and no exposure to radiation compared with nuclear stress tests. Imagify was designed to be used with commercially available ultrasound equipment and established imaging techniques. More than 10 million stress imaging procedures are done each year in the U.S. to detect heart disease, the leading cause of death in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The Company estimates that the potential annual U.S. market opportunity for Imagify exceeds $2 billion. About Acusphere, Inc. Acusphere (NASDAQ: ACUS) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's initial product candidates were created using proprietary technology that enables Acusphere to control the porosity porosity /po·ros·i·ty/ (por-os´it-e) the condition of being porous; a pore. po·ros·i·ty n. 1. The state or property of being porous. 2. and size of nanoparticles and microparticles in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, Imagify, is a cardiovascular drug in Phase 3 clinical development. For more information about Acusphere visit the Company's web site at www.acusphere.com. "Acusphere" and "Imagify" are trademarks of Acusphere, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion